Tempus
Provides data and AI-driven precision medicine solutions for oncology clinics and researchers.
What they do
Tempus uses practical applications of artificial intelligence in healthcare to personalize cancer care. The company sequences genomic data and analyzes clinical notes, offering oncologists actionable insights to select the most effective therapies for individual cancer patients.
The record
- Vertical
- Oncology
- Sub-segment
- Precision medicine platform
- Product type
- Diagnostics
- Stage
- Public
- Headquarters
- Chicago, United States
- Region
- North America
- Founded
- 2015
- Total funding
- $1.4B raised
Notable investors: T. Rowe Price, Baillie Gifford, Franklin Templeton, Novo Holdings.